To SPAC or not to SPAC? It is a question increasingly asked of promising, privately owned biotechs, as health care investment groups, hedge fund managers, former CEOs, financial gurus and celebrities rushed to bring a record number of SPACs into the public markets last year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?